Helus Pharma Chief Growth Officer Paul Glavine Receives 248,000 RSUs

What Happened

Paul Glavine, Chief Growth Officer and a director of Helus Pharma (HELP), was granted 248,000 restricted stock units (RSUs) on September 30, 2026. The RSUs vested immediately; each RSU represents a right to receive one share of common stock. The filing lists no purchase price or dollar value for the award (transaction code A — Award/Grant).

Because the filing also reports the transfer of 230,939 shares previously held indirectly by the PLG Family Trust to the reporting person, Glavine’s beneficial ownership after the transaction is approximately 478,939 shares (248,000 RSUs + 230,939 transferred shares). This award is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-30 (award/vesting); Form 4 filed 2026-10-01 (timely).
• Transaction type/code: A — Grant/Award of RSUs; price listed as N/A; no dollar value reported in the filing.
• Shares acquired: 248,000 RSUs (each convertible to one share); shares transferred in: 230,939 (previously reported indirect holdings).
• Shares owned after transaction: ~478,939 beneficially owned shares (per filing footnote calculation).
• Notable footnotes:
  • F1: 248,000 RSUs granted on 9/30/2026 with immediate vesting.
  • F2: Each RSU equals one share of common stock.
  • F3: 230,941 previously reported indirect shares transferred to the reporting person; rounded to 230,939 in the filing.
• Filing timeliness: Filed the next day (timely under Form 4 rules); not marked late.

Context

RSU awards are a common form of executive compensation and, while they increase an insider’s stake, they are not the same signal as an open-market purchase. Immediate vesting means Glavine now has rights to the shares and could hold or sell them subject to company policies and trading windows. Retail investors should view this as a compensation-related increase in ownership rather than a clear bullish bet by the insider.